ℹ️
🇬🇧
Search
Search for people relevant for "LAMP2"
LAMP2
Person
Class
Person
Publication
Programmes
MUDr. Jindřich Kopecký Ph.D.
Academic staff at Faculty of Medicine in Hradec Králové
98 publications
Publications
publication
Prevention, diagnosis and treatment of cancer-associated thromboembolism
2023 |
Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
2023 |
Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
2023 |
Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
2023 |
Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
Percutaneous CT-guided Biopsy of Focal Liver Lesions-Long-term Experience with more than 300 Procedures
2023 |
Faculty of Medicine in Hradec Králové, Faculty of Education
publication
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
2023 |
First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
2023 |
Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
publication
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study
2023 |
First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
Combination of nivolumab and relatlimab – a new option in the treatment of malignant melanoma
2023 |
Faculty of Medicine in Hradec Králové
publication
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
2023 |
Faculty of Medicine in Pilsen
Load more publications (88)
Loading network view...